VIB4920 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 2 |
| 53 | Sjogren syndrome | 5 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04163991 (ClinicalTrials.gov) | December 9, 2019 | 12/11/2019 | A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | Drug: VIB4920;Drug: Placebo | Viela Bio | NULL | Completed | 18 Years | 99 Years | All | 78 | Phase 2 | United States;Poland |
| 2 | NCT02780388 (ClinicalTrials.gov) | May 12, 2016 | 3/5/2016 | A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis | A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis | Adult Onset Rheumatoid Arthritis | Drug: VIB4920;Other: Placebo | Viela Bio | NULL | Completed | 18 Years | 70 Years | All | 57 | Phase 1 | United States;Poland |
53. Sjogren syndrome
Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-002713-19-HU (EUCTR) | 30/12/2020 | 02/11/2020 | A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS) | Sjögren's syndrome MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: VIB4920 INN or Proposed INN: Not applicable Other descriptive name: MEDI4920 | Viela Bio, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 174 | Phase 2 | United States;Taiwan;Italy;United Kingdom;India;France;Hungary;Mexico;Argentina;Poland;Peru;China;Korea, Republic of | ||
| 2 | EUCTR2019-002713-19-IT (EUCTR) | 06/04/2020 | 17/06/2021 | A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren's Syndrome (SS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren's Syndrome (SS) - NA | Sjögren's syndrome MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: VIB4920 Product Code: [NA] | VIELABIO Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 174 | Phase 2 | United States;Greece;Spain;Turkey;Italy;United Kingdom;India;France;Hungary;Mexico;Argentina;Poland;Peru;China;Korea, Republic of | ||
| 3 | EUCTR2019-002713-19-PL (EUCTR) | 26/02/2020 | 22/11/2019 | A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS) | Sjögren's syndrome MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: VIB4920 INN or Proposed INN: Not applicable Other descriptive name: MEDI4920 | Viela Bio, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 174 | Phase 2 | United States;Greece;Spain;Turkey;Italy;United Kingdom;India;France;Hungary;Mexico;Argentina;Poland;Peru;China;Korea, Republic of | ||
| 4 | EUCTR2019-002713-19-GB (EUCTR) | 15/01/2020 | 21/11/2019 | A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) | Sjögren's syndrome MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: VIB4920 INN or Proposed INN: Not applicable Other descriptive name: MEDI4920 | Viela Bio, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 174 | Phase 2 | China;Korea, Republic of;United States;Greece;Turkey;United Kingdom;Italy;India;France;Mexico;Argentina;Poland;Peru | ||
| 5 | NCT04129164 (ClinicalTrials.gov) | October 16, 2019 | 2/10/2019 | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS) | Sjögren's Syndrome | Drug: VIB4920;Drug: Placebo | Viela Bio | NULL | Recruiting | 18 Years | 75 Years | All | 174 | Phase 2 | United States;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;United Kingdom |